Israeli drug maker, Teva Pharmaceuticals Industries Ltd. (ADR) (NYSE: TEVA) announced on Thursday that it will slash about 5,000 jobs, mainly by the end of next year as part of its broader restructuring plan, aimed at narrowing its oversized business and streamlining operations. The Company intends to focus on fast growing generic drug business as well as its core R&D programs. Teva expects to save $2 billion in annual costs by the end of 2017. Shares were gaining following the announcement. Teva, which is one the world’s leading generic drug maker, struggled in the recent past due to declining sales-trend in its both generic and branded-drugs segments.
Recent Comments